A Phase 1/2, Multicentre, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumours.
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid
tumours, and to see if it works to treat these solid tumours in children and young adults (≤
21 years old). After the final dose has been chosen, patients will be enrolled according to
the specific solid tumour type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see
how nab-paclitaxel works in treating these tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society